Duffy D M, Hess D L, Stouffer R L
Division of Reproductive Sciences, Oregon Regional Primate Research Center, Beaverton 97006.
J Clin Endocrinol Metab. 1994 Dec;79(6):1587-94. doi: 10.1210/jcem.79.6.7989460.
Colocalization of progesterone receptors and 3 beta-hydroxysteroid dehydrogenase (3 beta HSD), a key enzyme in progesterone biosynthesis, in macaque luteal cells suggest that progesterone has an autocrine role in the regulation of primate luteal function. To test this hypothesis, we administered trilostane, a 3 beta HSD inhibitor, to rhesus macaques at the midluteal phase of spontaneous menstrual cycles to rapidly and reversibly reduce progesterone production. Animals received trilostane (600 mg/dose; treated group; n = 5) or vehicle (control group; n = 4) orally on days 6-7 of the luteal phase. Trilostane significantly (P < 0.05) elevated pregnenolone levels within 1 h of treatment compared to those in vehicle-treated animals; after 1 day of treatment, the mean pregnenolone level (173 nmol/L) was 86-fold greater than the control value. Pregnenolone levels dropped after cessation of drug administration and became indistinguishable from control levels by day 13. Trilostane significantly reduced serum progesterone levels within 3 h of initial administration (P < 0.01), and levels remained near baseline (1.0 nmol/L) throughout the 2 days of treatment. Progesterone levels also remained low after cessation of trilostane treatment in four of five monkeys, and trilostane-treated animals experienced a shorter luteal phase than vehicle-treated animals (7.8 +/- 0.2 vs. 16 +/- 1 days; P < 0.01). Histological analysis (n = 3/group) revealed indexes of premature structural luteolysis by 4 days after the onset of trilostane administration. Exposure to trilostane had no effect on the percentage of luteal cells expressing progesterone receptors, as determined by immunocytochemistry. Serum LH levels were not different between treatment and control groups throughout the experimental period. As trilostane dramatically reduced serum progesterone and induced premature menses without major concurrent alteration in serum cortisol, we conclude that trilostane ios an effective, rapidly acting inhibitor of 3 beta HSD in the macaque corpus luteum during the midluteal phase of the menstrual cycle. Progesterone production did not typically resume after cessation of trilostane treatment despite continuing gonadotropin support luteolysis. Thus, progesterone or a related metabolite may be required to maintain the function and structural integrity of the primate corpus luteum during the normal menstrual cycle.
孕酮受体与3β - 羟基类固醇脱氢酶(3βHSD,孕酮生物合成中的关键酶)在猕猴黄体细胞中的共定位表明,孕酮在灵长类黄体功能调节中具有自分泌作用。为了验证这一假设,我们在恒河猴自发月经周期的黄体中期给予曲洛司坦(一种3βHSD抑制剂),以快速且可逆地降低孕酮生成。动物在黄体期的第6 - 7天口服曲洛司坦(600 mg/剂量;治疗组;n = 5)或赋形剂(对照组;n = 4)。与给予赋形剂的动物相比,曲洛司坦在治疗后1小时内显著(P < 0.05)提高了孕烯醇酮水平;治疗1天后,平均孕烯醇酮水平(173 nmol/L)比对照值高86倍。停药后孕烯醇酮水平下降,到第13天时与对照水平无差异。曲洛司坦在初次给药后3小时内显著降低血清孕酮水平(P < 0.01),且在整个2天的治疗过程中水平维持在接近基线(1.0 nmol/L)。在五只猴子中的四只,曲洛司坦治疗停止后孕酮水平也保持较低,且曲洛司坦治疗的动物黄体期比给予赋形剂的动物短(7.8 ± 0.2天对16 ± 1天;P < 0.01)。组织学分析(每组n = 3)显示,曲洛司坦给药开始后4天出现过早的黄体结构溶解指标。通过免疫细胞化学测定,暴露于曲洛司坦对表达孕酮受体的黄体细胞百分比没有影响。在整个实验期间,治疗组和对照组的血清LH水平没有差异。由于曲洛司坦显著降低血清孕酮并诱导过早月经,而血清皮质醇没有重大的同时改变,我们得出结论,曲洛司坦是月经周期黄体中期猕猴黄体中3βHSD的一种有效、快速起效的抑制剂。尽管持续有促性腺激素支持黄体溶解,但曲洛司坦治疗停止后孕酮生成通常不会恢复。因此,在正常月经周期中,可能需要孕酮或一种相关代谢物来维持灵长类黄体的功能和结构完整性。